RunaPharma
The abbreviated format does not require turnover, and these accounts state none. Without turnover there is no EBIT margin either.
Balance sheet
balance sheet total €189 on 30-06-2025in euro
in euro
Key figures and ratios
per financial year, computed from the annual accounts| Line | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017no balance total | 2016 | 2015 | 2014 | 2013 | 2012 | 201116 months |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | -917 | -437 | -6,283 | -15,220 | -1,646 | ||
| - | - | - | - | - | - | - | - | - | - | -979 | -521 | -6,281 | -15,975 | -1,873 | ||
| - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 1,568 | ||
| 35 | 75 | -963 | 1,035 | 7 | -37 | -1,006 | - | - | 320 | -652 | -1,421 | -32,477 | 19,846 | - | ||
| -18,060 | -16,767 | -14,379 | -13,534 | -13,361 | -12,093 | -11,024 | -10,076 | - | -7,978 | -7,198 | -6,218 | -4,797 | 30,583 | 16,559 | ||
| - | - | - | - | - | - | - | - | - | - | - | - | - | 3.9% | 81.7% | ||
| - | - | - | - | - | - | - | - | - | - | - | - | - | 8.71 | 5.19 | ||
| - | - | - | - | - | - | - | - | - | - | - | - | - | 24.37 | 0.22 | ||
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | -13.1% | ||
| - | - | - | - | - | - | - | - | - | - | - | - | - | -46.1% | -10.7% |
The ratios are withheld because a balance sheet total of €189 is too small for a meaningful ratio.
A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.
Filed annual accounts
as filed with the National Bank, click a year to choose it| Line | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017no balance total | 2016 | 2015 | 2014 | 2013 | 2012 | 201116 months |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet: assets | ||||||||||||||||
20/58 |
189 | 154 | 79 | 1,043 | 7 | 0 | 37 | 1,043 | - | 320 | 0 | 834 | 2,569 | 35,360 | 21,630 | |
21/28 |
- | - | - | - | - | - | - | - | - | - | - | 183 | 497 | 810 | 1,124 | |
22/27 |
- | - | - | - | - | - | - | - | - | - | - | 183 | 497 | 810 | 1,124 | |
23 |
- | - | - | - | - | - | - | - | - | - | - | 183 | 497 | 810 | 1,124 | |
29/58 |
189 | 154 | 79 | 1,043 | 7 | 0 | 37 | 1,043 | - | 320 | 0 | 652 | 2,073 | 34,550 | 20,506 | |
40/41 |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | 5,802 | |
40 |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | 4,293 | |
41 |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | 1,509 | |
54/58 |
189 | 154 | 79 | 1,043 | 7 | 0 | 37 | 1,043 | - | 320 | 0 | 652 | 2,073 | 34,550 | 14,704 | |
| Balance sheet: equity and liabilities | ||||||||||||||||
10/49 |
189 | 154 | 79 | 1,043 | 7 | 0 | 37 | 1,043 | - | 320 | 0 | 834 | 2,569 | 35,360 | 21,630 | |
10/15 |
-18,060 | -16,767 | -14,379 | -13,534 | -13,535 | -12,267 | -11,197 | -10,076 | -9,473 | -8,326 | -7,198 | -6,035 | -5,201 | 1,394 | 17,682 | |
10/11 |
20,000 | 20,000 | 20,000 | 20,000 | 20,000 | 0 | 20,000 | 20,000 | 20,000 | 20,000 | 20,000 | 20,000 | 20,000 | 20,000 | 20,000 | |
100 |
- | - | - | - | - | 0 | 20,000 | 20,000 | 20,000 | 20,000 | 20,000 | 20,000 | 20,000 | 20,000 | 20,000 | |
11 |
- | - | - | - | - | 20,000 | - | - | - | - | - | - | - | - | - | |
1100/10 |
- | - | - | - | - | 20,000 | - | - | - | - | - | - | - | - | - | |
14 |
-38,060 | -36,767 | -34,379 | -33,534 | -33,535 | -32,267 | -31,197 | -30,076 | -29,473 | -28,326 | -27,198 | -26,035 | -25,201 | -18,606 | -2,318 | |
17/49 |
18,249 | 16,922 | 14,458 | 14,576 | 13,542 | 12,267 | 11,234 | 11,119 | 9,473 | 8,645 | 7,198 | 6,870 | 7,770 | 33,967 | 3,948 | |
17 |
- | - | - | - | - | - | - | - | - | - | - | - | - | 30,000 | - | |
170/4 |
- | - | - | - | - | - | - | - | - | - | - | - | - | 30,000 | - | |
42/48 |
18,249 | 16,922 | 14,458 | 14,576 | 13,368 | 12,093 | 11,060 | 11,119 | 9,473 | 8,298 | 7,198 | 6,870 | 6,870 | 3,967 | 3,948 | |
43 |
- | - | - | - | - | - | - | - | - | - | 28 | - | - | - | - | |
430/8 |
- | - | - | - | - | - | - | - | - | - | 28 | - | - | - | - | |
44 |
- | - | 0 | 118 | - | - | - | 58 | - | - | - | - | - | - | - | |
440/4 |
- | - | 0 | 118 | - | - | - | 58 | - | - | - | - | - | - | - | |
45 |
- | - | - | - | - | - | - | - | - | - | - | - | - | 19 | - | |
450/3 |
- | - | - | - | - | - | - | - | - | - | - | - | - | 19 | - | |
47/48 |
18,249 | 16,922 | 14,458 | 14,458 | 13,368 | 12,093 | 11,060 | 11,060 | 9,473 | 8,298 | 7,170 | 6,870 | 6,870 | 3,948 | 3,948 | |
492/3 |
- | - | - | 0 | 174 | 174 | 174 | - | - | 348 | - | - | 900 | - | - | |
| Income statement | ||||||||||||||||
76A |
- | - | - | - | - | - | - | 1,043 | - | - | - | - | - | - | - | |
9900 |
-659 | -1,856 | -357 | 139 | -790 | -593 | -797 | -107 | -654 | -534 | -324 | 203 | -5,731 | -14,699 | -843 | |
630 |
- | - | - | - | - | - | - | - | - | - | 183 | 314 | 314 | 314 | 444 | |
640/8 |
590 | 493 | 450 | 101 | 448 | 446 | 270 | 442 | 440 | 594 | 593 | 640 | 552 | 521 | 802 | |
9901 |
-1,250 | -2,349 | -806 | 38 | -1,238 | -1,038 | -1,067 | -549 | -1,094 | -1,128 | -1,100 | -751 | -6,596 | -15,533 | -2,090 | |
75/76B |
- | - | - | 0 | 1 | - | - | 1 | - | - | 0 | - | 0 | 89 | 10 | |
75 |
- | - | - | 0 | 1 | - | - | 1 | - | - | 0 | - | 0 | 89 | 10 | |
65/66B |
44 | 39 | 39 | 37 | 30 | 31 | 54 | 55 | 54 | - | 63 | 84 | -2 | 843 | 236 | |
65 |
44 | 39 | 39 | 37 | 30 | 31 | 54 | 55 | 54 | - | 63 | 84 | -2 | 843 | 236 | |
9903 |
-1,293 | -2,388 | -845 | 1 | -1,268 | -1,069 | -1,121 | -603 | -1,148 | -1,128 | -1,162 | -835 | -6,594 | -16,287 | -2,316 | |
67/77 |
- | - | - | - | - | - | - | - | - | - | - | - | 0 | 2 | 1 | |
9904 |
-1,293 | -2,388 | -845 | 1 | -1,268 | -1,069 | -1,121 | -603 | -1,148 | -1,128 | -1,162 | -835 | -6,594 | -16,289 | -2,318 | |
9905 |
-1,293 | -2,388 | -845 | 1 | -1,268 | -1,069 | -1,121 | -603 | -1,148 | -1,128 | -1,162 | -835 | -6,594 | -16,289 | -2,318 | |
| Appropriation of the result | ||||||||||||||||
9906 |
-38,060 | -36,767 | -34,379 | -33,534 | -33,535 | -32,267 | -31,197 | -30,076 | -29,473 | -28,326 | -27,198 | -26,035 | -25,201 | -18,606 | -2,318 | |
14P |
-36,767 | -34,379 | -33,534 | -33,535 | - | - | - | - | - | - | - | - | - | - | - | |
| Document | ||||||||||||||||
The full notes are in the filed accounts (PDF).
Source: Annual accounts 2025 (PDF), filed on 09-12-2025.
Filings
each dot is a set of accounts, on the day it reached the National Bank| Financial year | Type | Filed | Reference | Document |
|---|---|---|---|---|
| 30-06-2025 | abbreviated format | 09-12-2025 | 2025-00579347 | |
| 30-06-2024 | abbreviated format | 17-01-2025 | 2025-00007080 | |
| 30-06-2023 | abbreviated format | 11-12-2023 | 2023-00526804 | |
| 30-06-2022 | abbreviated format | 19-12-2022 | 2022-20541788 | |
| 30-06-2021 | abbreviated format | 21-12-2021 | 2021-80800448 | |
| 30-06-2020 | abbreviated format | 29-01-2021 | 2021-02400484 | |
| 30-06-2019 | abbreviated format | 23-01-2020 | 2020-01900106 | |
| 30-06-2018 | abbreviated format | 20-12-2018 | 2018-74800540 | |
| 30-06-2017 | abbreviated format | 19-12-2017 | 2017-72100211 | |
| 30-06-2016 | abbreviated format | 06-12-2016 | 2016-69400365 | |
| 30-06-2015 | abbreviated format | 07-12-2015 | 2015-68400060 | |
| 30-06-2014 | abbreviated format | 08-12-2014 | 2014-68500279 | |
| 30-06-2013 | abbreviated format | 11-12-2013 | 2013-68100469 | |
| 30-06-2012 | abbreviated format | 04-12-2012 | 2012-65500086 | |
| 30-06-2011 | abbreviated format | 07-12-2011 | 2011-63100006 |
Insights on RunaPharma
The operating result for 2025 is a loss of €1,250, smaller than the loss of €2,349 in 2024.
Equity is negative. Debt of €18,249 exceeds the balance-sheet total of €189.